Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 1997

View Archived Issues

Pharmacia & Upjohn describes HIV reverse transcriptase inhibitors

Japanese scientists report cholecystokinin antagonists

Potent antitumor agents described by Daiichi

Antifungal agent described by Roussel Morishita

New MDR modulators disclosed by Vertex

New antimigraine agent from Pfizer

PDE IV inhibitors revealed by Byk Gulden

New COX-2 inhibitor series reported by Merck Frosst

New PDE IV/TNF inhibitors from Chiroscience

Searle describes antiinflammatory oxazoles

Xoma expands pivotal Neuprex trials

Boston Life Sciences accelerates development of Altropane

AEterna accelerates anticancer clinical program

FDA proposes withdrawal of terfenadine products

Third set of phase III trials on Diatide imaging agent commences

Combination protease inhibitor trial with 141W94/VX-478

FDA clears antimetastatic carbohydrate compound for human trials

Aronex out-licenses antibody-toxin complex

Inhale/Centeon agreement for alpha1-proteinase inhibitor

SyStemix to be integrated into Novartis

Gene Logic/Baylor prostate cancer collaboration

Stanford researchers isolate breast cancer gene

Roche/Genentech marketing agreement for Roferon-A

3DP and ViroPharma establish drug discovery collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...